Compare JVA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JVA | MDXH |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 21.1M |
| IPO Year | 1997 | 2021 |
| Metric | JVA | MDXH |
|---|---|---|
| Price | $3.53 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 48.1K | ★ 228.8K |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $10.70 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $0.40 |
| 52 Week High | $5.62 | $5.33 |
| Indicator | JVA | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 52.68 |
| Support Level | $3.26 | $0.40 |
| Resistance Level | $3.57 | $3.79 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 87.14 | 87.60 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.